Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Taxanes are an established option in the standard treatment paradigm for patients with metastatic breast cancer (MBC). Neuropathy is a common, dose-limiting side effect of taxane therapy that is often managed by dose reductions and delays. The severity, time to onset, and improvement in neuropathy are important considerations for patient management and vary among currently approved taxanes. The rate of grade ≥3 neuropathy with taxanes has been shown to be dose and schedule dependent; however, time to improvement to grade ≤1 is typically shorter for nab-paclitaxel than for other taxanes in patients with MBC. Many tools for assessing patient-reported neuropathy exist. Because MBC is incurable and patient quality of life must be critically considered when making treatment decisions, there is a need for more prospective trials to assess patient-reported neuropathy. Validated predictors of taxane-related neuropathy may play an important role in treatment decisions in the future. This review will focus on the toxicity profile (i.e., neuropathy) of each of the taxanes used in the treatment of MBC, will provide updates on tools used for the assessment of neuropathy, and will highlight newly discovered predictors of taxane-related neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other common symptoms among cancer patients (e.g., nausea, neuropathy, swelling of arms and legs, hot flashes, cognitive problems) have received less attention in the MBC literature [6, 12–14].”
From Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility (2017) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081 · cited 1×
“[85] Metastatic or locally advanced, previously treated (346) Paclitaxel 90 mg/m(2) weekly for 3 of 4 weeks NR 17 <1”
BackgroundGradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 1×
“[17] Metastatic, previously treated (229) nab-Paclitaxel 260 mg/m(2) q3w NR 10 0”
Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,014
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897 · cited 1×
“[84] Metastatic or locally advanced, previously treated (231) Docetaxel 100 mg/m(2) q3w NR 2 (grade 3 or higher)”
BackgroundAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756 · cited 1×
“With respect to taxane-based therapy, in an exploratory analysis of a phase III trial in patients with advanced non-small cell lung cancer, those with diabetes who were treated with nab-paclitaxel plus carboplatin had a 4 % higher rate of grade ≥3 peripheral neuropathy (7 %) than did the intent-to-treat population (3…”
Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594 · cited 2×
“[29] Metastatic, previously treated (225) Paclitaxel 175 mg/m(2) q3w 21 12 0”
BackgroundPharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Research works printed but not linked: 1
- Hirsh V, Owen SP, Ko A, Renschler MF, Socinski MA (2013) nab-Paclitaxel in combination with carboplatin as first-line therapy in diabetic patients with advanced non-small cell lung cancer (NSCLC). In: 15th World conference on lung cancer, poster P1 10-044
Cited by
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
“Chemotherapy with taxanes often leads to neuropathy, which can persist long after treatment ends.(35) Anthracyclines and HER-2–targeted drugs can lead to cardiomyopathy and congestive heart failure.”
BackgroundCancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Seca, A., & Pinto, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010263 · Cited by 686
“Higher doses of nab-paclitaxel can be administered over a shorter infusion time, and consequently, there is an improvement in neuropathy side effects after the therapy discontinuation [57], although peripheral sensory neuropathy occurred more frequently with nab-paclitaxel compared to paclitaxel [55].”
BackgroundMetastatic and triple-negative breast cancer: challenges and treatment options
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0551-3 · Cited by 524
“anthracycline-resistant MBC cases [131, 132].”
Background
Metadata
- Authors
- Rivera, E., & Cianfrocca, M.
- Affiliations
- Banner MD Anderson Cancer Center (US)
- Corresponding author
- Rivera, Edgardo
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2015-01-18
- Volume
- 75
- Issue
- 4
- Pages
- 659-670
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC4365177
- OpenAlex
- W2061239263
- Cited by
- 159
- References
- 89
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 11 · 2023: 14 · 2022: 19 · 2021: 15 · 2020: 19 · 2019: 7 · 2018: 14 · 2017: 16 · 2016: 14 · 2015: 8
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Celgene
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- taxanes, neuropathy, metastatic breast cancer, nab-paclitaxel, paclitaxel, docetaxel, chemotherapy toxicity, dose-limiting toxicity, patient-reported outcomes, quality of life
- MeSH terms
- Antineoplastic Agents, Breast Neoplasms, Clinical Trials as Topic, Drug Administration Schedule, Female, Humans, Neoplasm Metastasis, Neuralgia, Taxoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. https://app.cochat.ai/papers/10.1007/s00280-014-2607-5
- The paper
- Rivera, E., & Cianfrocca, M. (2015). Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-014-2607-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.